Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
暂无分享,去创建一个
[1] D. Murrell,et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. , 2011, Journal of the American Academy of Dermatology.
[2] L. Strowd,et al. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. , 2011, Journal of the American Academy of Dermatology.
[3] R. Eming,et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. , 2009, The Journal of investigative dermatology.
[4] H. Shimizu,et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. , 2009, Journal of the American Academy of Dermatology.
[5] D. Keskin,et al. A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.
[6] L. Borradori,et al. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. , 2008, The Journal of investigative dermatology.
[7] J. Roujeau,et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. , 2008, The Journal of investigative dermatology.
[8] T. Nishikawa,et al. Anti‐desmoglein IgG autoantibodies in patients with pemphigus in remission , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] H. Shimizu,et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.
[10] E. Bröcker,et al. Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders , 2008, Clinical reviews in allergy & immunology.
[11] B. Thiers. A Single Cycle of Rituximab for the Treatment of Severe Pemphigus , 2008 .
[12] J. Roujeau,et al. A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.
[13] R. Corona,et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. , 2007, Archives of dermatology.
[14] L. Cavacini,et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.
[15] R. Paus,et al. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'? , 2006, Experimental Dermatology.
[16] M. Amagai. Desmoglein as a target in autoimmunity and infection. , 2003, Journal of the American Academy of Dermatology.
[17] E. Ruocco,et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. , 2002, Archives of dermatology.
[18] T. Nishikawa,et al. Monitoring disease activity in pemphigus with enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 , 2002, The British journal of dermatology.
[19] P. Seed,et al. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels , 2001, The British journal of dermatology.
[20] T. Nishikawa,et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. , 1999, Journal of the American Academy of Dermatology.
[21] Komai,et al. Usefulness of enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus , 1999, The British journal of dermatology.
[22] J. Bystryn,et al. Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. , 1997, Journal of the American Academy of Dermatology.
[23] A. Ahmed,et al. Influence of treatment on the clinical course of pemphigus vulgaris. , 1996, Journal of the American Academy of Dermatology.
[24] J. Bystryn,et al. The adjuvant therapy of pemphigus. An update. , 1996, Archives of dermatology.
[25] J. Thivolet,et al. Weaning of systemic steroid treatment in pemphigus : a twelve-year retrospective study on 270 French patients , 1995 .
[26] J. Stanley. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. , 1993, Advances in immunology.
[27] J. Stanley. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. , 1989, The Journal of clinical investigation.
[28] J. Bystryn. Adjuvant therapy of pemphigus. , 1984, Archives of dermatology.
[29] W. F. Lever. Pemphigus and pemphigoid: A review of the advances made since 1964 , 1979 .